Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2019
Oxytocin modulates hippocampal perfusion in people at clinical high risk for psychosis.
Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Preventive Treatments for Psychosis: Umbrella Review (Just the Evidence).Frontiers in psychiatry · 2019Pooled it
- Connectome dysfunction in patients at clinical high risk for psychosis and modulation by oxytocin.Molecular psychiatry · 2024Trial
- Acute oxytocin effects in inferring others' beliefs and social emotions in people at clinical high risk for psychosis.Translational psychiatry · 2020Trial
- Investigating resting brain perfusion abnormalities and disease target-engagement by intranasal oxytocin in women with bulimia nervosa and binge-eating disorder and healthy controls.Translational psychiatry · 2020Trial
- Biomarkers for Psychosis: Are We There Yet? Umbrella Review of 1478 Biomarkers.Schizophrenia bulletin open · 2024Article
- Unlocking potential of oxytocin: improving intracranial lymphatic drainage for Alzheimer's disease treatment.Theranostics · 2024Article
- Reduced cortical cerebral blood flow in antipsychotic-free first-episode psychosis and relationship to treatment response.Psychological medicine · 2023Article
- Oxytocin as a treatment for high-risk psychosis or early stages of psychosis: a mini review.Frontiers in psychiatry · 2023Review
- Parsing neurobiological heterogeneity of the clinical high-risk state for psychosis: A pseudo-continuous arterial spin labelling study.Frontiers in psychiatry · 2023Article
- Oxytocin in Women's Health and Disease.Frontiers in endocrinology · 2022Review
- Advances and Challenges in Intranasal Delivery of Antipsychotic Agents Targeting the Central Nervous System.Frontiers in pharmacology · 2022Review
- Interactions between hippocampal activity and striatal dopamine in people at clinical high risk for psychosis: relationship to adverse outcomes.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021Article
- Progression from being at-risk to psychosis: next steps.NPJ schizophrenia · 2020Review
- Intranasal oxytocin increases heart-rate variability in men at clinical high risk for psychosis: a proof-of-concept study.Translational psychiatry · 2020Article
- Basic Self-Disturbances Related to Reduced Anterior Cingulate Volume in Subjects at Ultra-High Risk for Psychosis.Frontiers in psychiatry · 2019Article
- Pan-London Network for Psychosis-Prevention (PNP).Frontiers in psychiatry · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 2 institutions in 2 countries.
Funding
Abstract
Preclinical and human studies suggest that hippocampal dysfunction is a key factor in the onset of psychosis. People at Clinical High Risk for psychosis (CHR-P) present with a clinical syndrome that can include social withdrawal and have a 20-35% risk of developing psychosis in the next 2 years. Recent research shows that resting hippocampal blood flow is altered in CHR-P individuals and predicts adverse clinical outcomes, such as non-remission/transition to frank psychosis. Previous work in healthy males indicates that a single dose of intranasal oxytocin has positive effects on social function and marked effects on resting hippocampal blood flow. The present study examined the effects of intranasal oxytocin on hippocampal blood flow in CHR-P individuals. In a double-blind, placebo-controlled, crossover design, 30 CHR-P males were studied using pseudo-continuous Arterial Spin Labelling on 2 occasions, once after 40IU intranasal oxytocin and once after placebo. The effects of oxytocin on left hippocampal blood flow were examined in a region-of-interest analysis of data acquired at 22-28 and at 30-36 minutes post-intranasal administration. Relative to placebo, administration of oxytocin was associated with increased hippocampal blood flow at both time points (p = .0056; p = .034), although the effect at the second did not survive adjustment for the effect of global blood flow. These data indicate that oxytocin can modulate hippocampal function in CHR-P individuals and therefore merits further investigation as a candidate novel treatment for this group.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.